[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR900017586A - 케탄세린(ketanserin) 유도체 - Google Patents

케탄세린(ketanserin) 유도체 Download PDF

Info

Publication number
KR900017586A
KR900017586A KR1019900004563A KR900004563A KR900017586A KR 900017586 A KR900017586 A KR 900017586A KR 1019900004563 A KR1019900004563 A KR 1019900004563A KR 900004563 A KR900004563 A KR 900004563A KR 900017586 A KR900017586 A KR 900017586A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
compound
addition salt
ace inhibitor
ketanserine
Prior art date
Application number
KR1019900004563A
Other languages
English (en)
Inventor
아쏘구나 쥬세페
루체티 지오반니
Original Assignee
구스타프 반 리이트
쟈안센 파아마슈우티카 엔 부이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 구스타프 반 리이트, 쟈안센 파아마슈우티카 엔 부이 filed Critical 구스타프 반 리이트
Publication of KR900017586A publication Critical patent/KR900017586A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

케탄세린(KETANSERIN) 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 유효성분으로 케탄세린 화합물 또는그산부가염과 ACE억제제 화합물 또는 그 산부가염이나 염기부가염을 혈압강하 상승 효과량 조성하고 담체를 배합한 약제 조성물.
  2. 제1항에 있어서, ACE억제제 화합물을 베나제프릴, 켑토프릴, 에날라프릴, 에날라프릴라트, 리시노프릴, 알라세프릴, 델라라프릴, 모벨티프릴, 라미프릴, 라미프릴라트, 페린도프릴, 페린도프릴라트, 퀴나프릴, 퀴나프릴라트, 실라자프릴, 실라자프릴라트, 포시노프릴, 인돌라프릴, 스필라프릴, 스필라프릴라트 및 조페노프릴로부터 선택하는 약제 조성물.
  3. 제1항에 있어서, ACE 억제제가 다음 구조식의 부분을 함유하는 화합물인 약제 조성물.
    위의 식에서 R1은 수소 또는 에틸이고, R2는 수소 또는 아미노프릴이고, R3은 수소이거나, R2및 R3은 함께 1,2-에탄디일을 형성하고, X는 CH 또는 N이고, n은 2 또는 3이다.
  4. 제1항 내지 제3항의 어느 한항에 있어서, ACE억제제에 대한 게탄세린 화합물의 몰비가 약 10:1 내지 약1:10인 약제조성물.
  5. 제4항에 있어서, 몰비가 약 5:1 내지 약1:5인 약제조성물.
  6. 제1항에 있어서, 켑토프릴에 대한 케탄세린의 몰비가 1:2 내지 1:3이거나 1:1 내지 1:15인 약제조성물.
  7. 제1항에 있어서, 에날라프릴 또는 실라자프릴에 대한 케탄세린의 몰비가10:1 내지 1:1인 약제조성물.
  8. 유효성분 화합물과 담체를 즉시 혼합하여 제1항 내지 제7항의 각 상승효능 약제조성물을 제조하는 방법.
  9. 케탄세린화합물 또는 그산부가염과, ACE억제제 또는 그산부가염이나 염기부가염으로 조성된 동시 투여, 분리투여 또는 연속투여용 배합제제 생성물.
  10. 혈압강하제 투여치료대상 온혈 동물에게 제1항 내지 제7항의 각 약제조성물의 혈압강하 효과량을 동시에, 따로 분리하여 또는 연속하여 고혈압증상을 치료하는방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900004563A 1989-04-05 1990-04-03 케탄세린(ketanserin) 유도체 KR900017586A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33347189A 1989-04-05 1989-04-05
US333471 1989-04-05

Publications (1)

Publication Number Publication Date
KR900017586A true KR900017586A (ko) 1990-12-19

Family

ID=23302937

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900004563A KR900017586A (ko) 1989-04-05 1990-04-03 케탄세린(ketanserin) 유도체

Country Status (9)

Country Link
EP (1) EP0391462A1 (ko)
JP (1) JPH02290823A (ko)
KR (1) KR900017586A (ko)
AU (1) AU5295790A (ko)
CA (1) CA2013801A1 (ko)
IL (1) IL93990A0 (ko)
NZ (1) NZ233122A (ko)
PT (1) PT93654A (ko)
ZA (1) ZA902602B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073539A (en) * 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
YU48602B (sh) * 1991-11-25 1998-12-23 Krka Tovarna Zdravil P.O. Postupak za dobijanje stabilne formulacije soli enalaprila
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
AU2004295058B9 (en) 2003-11-20 2011-06-30 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
ES2551027T3 (es) 2003-11-20 2015-11-13 Janssen Pharmaceutica Nv 2-Quinolinonas 7-fenilalquil sustituidas y 2-quinoxalinonas como inhibidores de poli(ADP-ribosa) polimerasa
ES2415771T3 (es) * 2004-06-30 2013-07-26 Janssen Pharmaceutica N.V. Derivados de quinazolina como inhibidores de PARP
WO2006003150A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
JP4852540B2 (ja) 2004-06-30 2012-01-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのフタラジン誘導体
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624082D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril metal salts
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
JP5525447B2 (ja) 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
JP5464609B2 (ja) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
CN109157507A (zh) * 2018-09-14 2019-01-08 上海禾丰制药有限公司 酒石酸酮色林注射液及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln

Also Published As

Publication number Publication date
NZ233122A (en) 1991-10-25
JPH02290823A (ja) 1990-11-30
PT93654A (pt) 1990-11-20
CA2013801A1 (en) 1990-10-05
AU5295790A (en) 1990-10-11
IL93990A0 (en) 1991-01-31
EP0391462A1 (en) 1990-10-10
ZA902602B (en) 1991-12-24

Similar Documents

Publication Publication Date Title
KR900017586A (ko) 케탄세린(ketanserin) 유도체
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
UA40578C2 (uk) Сульфоніламінопіримідини і фармацевтичний препарат на їх основі
DE69534538D1 (de) Verzögerte Freisetzung von Peptiden aus pharmazeutischen Zusammensetzungen
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
EA200101005A1 (ru) Высокоэффективные композиции, содержащие дигидроэрготамин
JPS63104931A (ja) 酸化に対して安定化された薬剤組成物
DE68906609D1 (de) Dopamin-vorlaeufer.
DE60002126D1 (de) Substituierte dimere Carboxamid-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
DE69828615D1 (de) Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
RU98103388A (ru) (r)-5-бром-n-(1-этил-4-метилгексагидро-1н-1,4-диазепин-6-ил)-2-метокси-6-м етиламино-3-пиридинкарбоксамид, способ его получения и фармацевтическая композиция, содержащая указанное соединение
JP2001064205A (ja) 製剤組成物
RU98100111A (ru) Активирующая остеогенез фармацевтическая композиция
KR880004810A (ko) 소화성 궤양 치료제
EP0331948B1 (en) Pharmaceutical composition for the transdermal administration of heparin
ATE86965T1 (de) Pharmazeutische kompositionen zum behandeln von adrenoleukodystrophie.
KR890001559A (ko) 트라피딜을 함유하는 제약 조성물, 그의 제조방법 및 관련된 치료 용도
ES2138668T3 (es) Nuevos derivados de peptidos terapeuticamente activos en la cadena de coagulacion sanguinea, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
JPH0311022A (ja) 薬剤組成物
KR890012651A (ko) 이뇨제 또는 항고혈압제 조성물
KR930001906A (ko) 벤즈이미다졸린-2-옥소-1-카복실산 유도체의 용도

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid